Axsome Therapeutics Inc.
Axsome Therapeutics Announces Strong Q3 2024 Financial Results and Business Updates
Summary
Axsome Therapeutics, Inc. reported a significant increase in net product revenue for Q3 2024, driven by strong sales of Auvelity and Sunosi. The company updated its corporate presentation and provided progress updates on its developmental pipeline, including key clinical trial milestones. Total net product revenue for Q3 2024 was $104.8 million, an 81% year-over-year increase. Auvelity sales rose 113% to $80.4 million, while Sunosi revenue increased 21% to $24.4 million. The company is also preparing for the NDA submission for AXS-14 for fibromyalgia expected in November 2024. Further, the FDA has accepted the NDA resubmission for AXS-07 for the treatment of migraine with a PDUFA goal date of January 31, 2025.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement